Inogen, recognized as a global leader in medical technology, is focused on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions. The company’s products are widely available through partnerships with patients, prescribers, home medical equipment suppliers and distributors. With a gross profit margin of 44.22%, the company demonstrates strong pricing power in its market segment. With a gross profit margin of 44.22%, the company demonstrates strong pricing power in its market segment.
This fiscal growth is attributed to a significant increase in cross-company revenue, while Inogen continues to focus on stabilizing its direct-to-consumer revenue and increasing profitability. In 2024, Inogen introduced new products, including Rove 4, and received FDA approval for the SIMEOX 200 device, expanding its global product offering. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 2.66, according to InvestingPro analysis.
Kevin Smith, president and CEO of Inogen, expressed confidence in the company’s trajectory, highlighting a return to revenue growth, improved profitability and disciplined cost management. He highlighted Inogen’s commitment to delivering leading edge devices for respiratory patients. The market seems to share that confidence, as the stock has returned an impressive 59.7% over the past year, despite current profitability challenges. Subscribers to InvestingPro can access additional insights through a comprehensive Pro Research Report, which includes a detailed analysis of Inogen’s financial health and growth outlook.
Inogen will report its official financial results for the fourth quarter and full year 2024 after the market closes on February 25, 2025. A conference call hosted by Inogen management is scheduled for the same day at 2:00 PM PT / 5:00 PM ET. The call will be available to interested parties via a live audio webcast on the Inogen Investor Relations website, with an archived recording available for six months.
Inogen, recognized as a global leader in medical technology, is focused on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions. The company’s products are widely available through partnerships with patients, prescribers, home medical equipment suppliers and distributors.
The information in this article is based on a press release from Inogen, Inc.
In other recent news, Inogen Inc (NASDAQ:). reported a 6% year-over-year increase in revenue to $89 million in its third-quarter earnings report, driven by a 20% increase in business-to-business sales. Despite a 23.2% decline in direct-to-consumer sales, the medical technology company raised its full-year revenue forecast, which is now set between $329 million and $331 million, indicating growth of 4% to 5%. It also reported a significant improvement in gross margin to 46.5%.
Inogen has launched its new product, the Rove 4 portable oxygen concentrator, and continues its discussions with the FDA regarding Simeox, marking its focus on innovation and market expansion. The company generated $3 million in positive cash flow and reported adjusted EBITDA of $0.5 million. However, it posted a GAAP net loss of $6 million, although that was an improvement from last year’s loss of $45.7 million.
These recent developments reflect a company in transition, balancing growth in the business-to-business segment with a restructured approach to direct-to-consumer sales. Improved gross margin and positive adjusted EBITDA demonstrate Inogen’s shift toward profitability. With a strong cash position and no debt, Inogen appears financially stable as it continues to innovate and expand its market reach.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
